VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs
VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM